Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Are thiazolidinediones associated with an increased risk of heart failure and cardiovascular death?

Nature Clinical Practice Cardiovascular Medicine volume 5, pages 244–245 (2008)Cite this article

Access through your institution
Buy or subscribe

boxed-textLago RM et al. (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370: 1129–1136

Background

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Yki-Järvinen H (2004) Thiazolidinediones. N Engl J Med 351: 1106–1118

    Article  Google Scholar 

  2. Dargie HJ et al. (2007) A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 49: 1696–1704

    Article  CAS  Google Scholar 

  3. Nissen SE and Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457–2471

    Article  CAS  Google Scholar 

  4. Home PD et al. for the RECORD Study Group (2007) Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med 357: 28–38

    Article  CAS  Google Scholar 

  5. Dormandy JA et al. for the PROactive investigators (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279–1289

    Article  CAS  Google Scholar 

  6. Ghanim H et al. (2006) Low dose rosiglitazone exerts an anti-inflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics J Clin Endocrinol Metab 91: 3553–3558

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. and Distinguished Professor of Medicine and Chief of the Division of Endocrinology at the State University of New York (SUNY) at Buffalo, P Dandona is the Director of the Diabetes–Endocrinology Center of Western New York, NY, USA.,

    Paresh Dandona

  2. A Chaudhuri is Associate Director of the Diabetes and Endocrinology Center at Kaleida Health, Assistant Professor of Medicine and Program Director of the Endocrinology Fellowship Program at the SUNY at Buffalo.,

    Ajay Chaudhuri

Authors
  1. Paresh Dandona
    View author publications

    Search author on:PubMed Google Scholar

  2. Ajay Chaudhuri
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Paresh Dandona.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dandona, P., Chaudhuri, A. Are thiazolidinediones associated with an increased risk of heart failure and cardiovascular death?. Nat Rev Cardiol 5, 244–245 (2008). https://doi.org/10.1038/ncpcardio1121

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncpcardio1121

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing